Diverse Roles for the Paxillin Family of Proteins in Cancer

Genes and Cancer

Volumn 3, Issue 5-6, 2012, Pages 362-370

  Deakin, Nicholas O ^a   Pignatelli, Jeanine ^a   Turner, Christopher E ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

cell adhesion; cell survival; epithelial mesenchymal transition (EMT); extracellular matrix (ECM); invasion

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CORTACTIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 27; LEUPAXIN; PAXILLIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN HIC5; PROTEIN KINASE C; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VINCULIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; METASTASIS; NEOPLASM; OROPHARYNX CANCER; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84875529593     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912458582     Document Type: Article

References (150)

1. Joyce JA,Pollard JW.Microenvironmental regulation of metastasis.Nat Rev Cancer. 2009;9 (4): 239-52.
2. Hynes RO.Integrins: bidirectional, allosteric signaling machines.Cell. 2002;110 (6): 673-87.
3. Brown MC,Turner CE.Paxillin: adapting to change.Physiol Rev. 2004;84 (4): 1315-39.
4. Deakin NO,Turner CE.Paxillin comes of age.J Cell Sci. 2008;121 (Pt 15): 2435-44.
5. Turner CE.Paxillin interactions.J Cell Sci. 2000;113 (Pt 23): 4139-40.
6. Glenney JR,Zokas L.Novel tyrosine kinase substrates from rous sarcoma virus-transformed cells are present in the membrane skeleton.J Cell Biol. 1989;108 (6): 2401-8.
7. Turner CE,Glenney JR,Burridge K.Paxillin: a new vinculin-binding protein present in focal adhesions.J Cell Biol. 1990;111 (3): 1059-68.
8. Deakin NO,Ballestrem C,Turner CE.Paxillin and hic-5 interaction with vinculin is differentially regulated by Rac1 and RhoA.PLoS One. 2012;7 (5): e37990.
9. Denhez F,Wilcox-Adelman SA,Baciu PC, et al.Syndesmos, a syndecan-4 cytoplasmic domain interactor, binds to the focal adhesion adaptor proteins paxillin and hic-5.J Biol Chem. 2002;277 (14): 12270-4.
10. Hagel M,George EL,Kim A, et al.The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling.Mol Cell Biol. 2002;22 (3): 901-15.
11. Ishino K,Kaneyama Shibanuma M,Nose K.Specific decrease in the level of hic-5, a focal adhesion protein, during immortalization of mouse embryonic fibroblasts, and its association with focal adhesion kinase.J Cell Biochem. 2000;76 (3): 411-9.
12. Jones CA,Nishiya N,London NR, et al.Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity.Nat Cell Biol. 2009;11 (11): 1325-31.
13. Nishiya N,Tachibana K,Shibanuma M,Mashimo JI,Nose K.Hic-5-reduced cell spreading on fibronectin: competitive effects between paxillin and hic-5 through interaction with focal adhesion kinase.Mol Cell Biol. 2001;21 (16): 5332-45.
14. Nishiya N,Shirai T,Suzuki W,Nose K.Hic-5 interacts with GIT1 with a different binding mode from paxillin.J Biochem. 2002;132 (2): 279-89.
15. Nishiya N,Iwabuchi Y,Shibanuma M,Cote JF,Tremblay ML,Nose K.Hic-5, a paxillin homologue, binds to the protein-tyrosine phosphatase PEST (PTP-PEST) through its LIM 3 domain.J Biol Chem. 1999;274 (14): 9847-53.
16. Rathore VB,Okada M,Newman PJ,Newman DK.Paxillin family members function as csk-binding proteins that regulate lyn activity in human and murine platelets.Biochem J. 2007;403 (2): 275-81.
17. Turner CE,Brown MC,Perrotta JA, et al.Paxillin LD4 motif binds PAK and PIX through a novel 95-kD ankyrin repeat, ARF-GAP protein: a role in cytoskeletal remodeling.J Cell Biol. 1999;145 (4): 851-63.
18. Shola DT,Wang H,Wahdan-Alaswad R,Danielpour D.Hic-5 controls BMP4 responses in prostate cancer cells through interacting with smads 1, 5 and 8.Oncogene. 2012;31 (19): 2480-90.
19. Wang H,Song K,Sponseller TL,Danielpour D.Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling.J Biol Chem. 2005;280 (7): 5154-62.
20. Sheibani N,Tang Y,Sorenson CM.Paxillin's LD4 motif interacts with bcl-2.J Cell Physiol. 2008;214 (3): 655-61.
21. Woods AJ,Roberts MS,Choudhary J, et al.Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells.J Biol Chem. 2002;277 (8): 6428-37.
22. Woods AJ,Kantidakis T,Sabe H,Critchley DR,Norman JC.Interaction of paxillin with poly(A)-binding protein 1 and its role in focal adhesion turnover and cell migration.Mol Cell Biol. 2005;25 (9): 3763-73.
23. Mazaki Y,Hashimoto S,Sabe H.Monocyte cells and cancer cells express novel paxillin isoforms with different binding properties to focal adhesion proteins.J Biol Chem. 1997;272 (11): 7437-44.
24. Salgia R,Li JL,Lo SH, et al.Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.J Biol Chem. 1995;270 (10): 5039-47.
25. Yuminamochi T,Yatomi Y,Osada M, et al.Expression of the LIM proteins paxillin and hic-5 in human tissues.J Histochem Cytochem. 2003;51 (4): 513-21.
26. Kim-Kaneyama JR,Suzuki W,Ichikawa K, et al.Uni-axial stretching regulates intracellular localization of hic-5 expressed in smooth-muscle cells in vivo.J Cell Sci. 2005;118 (Pt 5): 937-49.
27. Shibanuma M,Mashimo J,Kuroki T,Nose K.Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence.J Biol Chem. 1994;269 (43): 26767-74.
28. Tumbarello DA,Brown MC,Hetey SE,Turner CE.Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin delta.J Cell Sci. 2005;118 (Pt 20): 4849-63.
29. Lipsky BP,Beals CR,Staunton DE.Leupaxin is a novel LIM domain protein that forms a complex with PYK2.J Biol Chem. 1998;273 (19): 11709-13.
30. Kaulfuss S,Grzmil M,Hemmerlein B, et al.Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.Mol Endocrinol. 2008;22 (7): 1606-21.
31. Sahu SN,Khadeer MA,Robertson BW,Nunez SM,Bai G,Gupta A.Association of leupaxin with src in osteoclasts.Am J Physiol Cell Physiol. 2007;292 (1): C581-90.
32. Sundberg-Smith LJ,DiMichele LA,Sayers RL,Mack CP,Taylor JM.The LIM protein leupaxin is enriched in smooth muscle and functions as a serum response factor cofactor to induce smooth muscle cell gene transcription.Circ Res. 2008;102 (12): 1502-11.
33. Kim-Kaneyama JR,Takeda N,Sasai A, et al.Hic-5 deficiency enhances mechanosensitive apoptosis and modulates vascular remodeling.J Mol Cell Cardiol. 2011;50 (1): 77-86.
34. Azuma K,Tanaka M,Uekita T, et al.Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma.Oncogene. 2005;24 (30): 4754-64.
35. Bhattacharjee A,Richards WG,Staunton J, et al.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.Proc Natl Acad Sci U S A. 2001;98 (24): 13790-5.
36. Cui W,Wang X,Liu YC,Wan YL,Guo HJ,Zhu J.Expression of HIC-5/ARA55 in colonrectal cancer and its mechanisms of action.Beijing Da Xue Xue Bao. 2006;38 (3): 280-3.
37. Farmer P,Bonnefoi H,Becette V, et al.Identification of molecular apocrine breast tumours by microarray analysis.Oncogene. 2005;24 (29): 4660-71.
38. Finak G,Bertos N,Pepin F, et al.Stromal gene expression predicts clinical outcome in breast cancer.Nat Med. 2008;14 (5): 518-27.
39. Kanteti R,Yala S,Ferguson MK,Salgia R.MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.J Environ Pathol Toxicol Oncol. 2009;28 (2): 89-98.
40. Mackinnon AC,Tretiakova M,Henderson L, et al.Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.J Clin Pathol. 2011;64 (1): 16-24.
41. Mestayer C,Blanchere M,Jaubert F,Dufour B,Mowszowicz I.Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines.Prostate. 2003;56 (3): 192-200.
42. Miyoshi Y,Ishiguro H,Uemura H, et al.Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.Prostate. 2003;56 (4): 280-6.
43. Nagata M,Fujita H,Ida H, et al.Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis.Int J Cancer. 2003;106 (5): 683-9.
44. Radvanyi L,Singh-Sandhu D,Gallichan S, et al.The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer.Proc Natl Acad Sci U S A. 2005;102 (31): 11005-10.
45. Richardson AL,Wang ZC,De Nicolo A, et al.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell. 2006;9 (2): 121-32.
46. Rodina A,Schramm K,Musatkina E,Kreuser ED,Tavitian A,Tatosyan A.Phosphorylation of p125FAK and paxillin focal adhesion proteins in src-transformed cells with different metastatic capacity.FEBS Lett. 1999;455 (1-2): 145-8.
47. Salgia R,Li JL,Ewaniuk DS, et al.Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.Oncogene. 1999;18 (1): 67-77.
48. Shi J,Wang S,Zhao E,Shi L,Xu X,Fang M.Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma.J Oral Pathol Med. 2010;39 (7): 548-51.
49. Turashvili G,Bouchal J,Baumforth K, et al.Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.BMC Cancer. 2007;7:55.
50. Yang HJ,Chen JZ,Zhang WL,Ding YQ.Focal adhesion plaque associated cytoskeletons are involved in the invasion and metastasis of human colorectal carcinoma.Cancer Invest. 2010;28 (2): 127-34.
51. Zhao H,Langerod A,Ji Y, et al.Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.Mol Biol Cell. 2004;15 (6): 2523-36.
52. Deakin NO,Turner CE.Distinct roles for paxillin and hic-5 in regulating breast cancer cell morphology, invasion, and metastasis.Mol Biol Cell. 2011;22 (3): 327-41.
53. Tanaka T,Moriwaki K,Murata S,Miyasaka M.LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin.Cancer Sci. 2010;101 (2): 363-8.
54. Jagadeeswaran R,Surawska H,Krishnaswamy S, et al.Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.Cancer Res. 2008;68 (1): 132-42.
55. Kim MS,Yoo NJ,Lee SH.Absence of paxillin gene mutation in lung cancer and other common solid cancers.Tumori. 2011;97 (2): 211-3.
56. Pallier K,Houllier AM,Le Corre D,Cazes A,Laurent-Puig P,Blons H.No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.Mol Carcinog. 2009;48 (7): 581-5.
57. Fujimoto N,Mizokami A,Harada S,Matsumoto T.Different expression of androgen receptor coactivators in human prostate.Urology. 2001;58 (2): 289-94.
58. Short SM,Yoder BJ,Tarr SM, et al.The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.Breast J. 2007;13 (2): 130-9.
59. Vadlamudi R,Adam L,Talukder A,Mendelsohn J,Kumar R.Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.Oncogene. 1999;18 (51): 7253-64.
60. Vadlamudi R,Adam L,Tseng B,Costa L,Kumar R.Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.Cancer Res. 1999;59 (12): 2843-6.
61. Yu JA,Deakin NO,Turner CE.Paxillin-kinase-linker tyrosine phosphorylation regulates directional cell migration.Mol Biol Cell. 2009;20 (22): 4706-19.
62. Hetey SE,Lalonde DP,Turner CE.Tyrosine-phosphorylated hic-5 inhibits epidermal growth factor-induced lamellipodia formation.Exp Cell Res. 2005;311 (1): 147-56.
63. Li X,Martinez-Ferrer M,Botta V,Uwamariya C,Banerjee J,Bhowmick NA.Epithelial hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.Oncogene. 2011;30 (2): 167-77.
64. Ren Y,Meng S,Mei L,Zhao ZJ,Jove R,Wu J.Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and src activation in response to epidermal growth factor.J Biol Chem. 2004;279 (9): 8497-505.
65. Tatsumi Y,Cho YY,He Z, et al.Involvement of the paxillin pathway in JB6 Cl41 cell transformation.Cancer Res. 2006;66 (11): 5968-74.
66. Tumbarello DA,Turner CE.Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA/ROCK-dependent pathway.J Cell Physiol. 2007;211 (3): 736-47.
67. Zhao Y,Zhang X,Guda K, et al.Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.Proc Natl Acad Sci U S A. 2010;107 (6): 2592-7.
68. Tarin D,Thompson EW,Newgreen DF.The fallacy of epithelial mesenchymal transition in neoplasia.Cancer Res. 2005;65 (14): 5996-6000.
69. Thompson EW,Newgreen DF,Tarin D.Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?.Cancer Res. 2005;65 (14): 5991-5.
70. Yang J,Weinberg RA.Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.Dev Cell. 2008;14 (6): 818-29.
71. Al-Hajj M,Clarke MF.Self-renewal and solid tumor stem cells.Oncogene. 2004;23 (43): 7274-82.
72. Hermann PC,Huber SL,Herrler T, et al.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.Cell Stem Cell. 2007;1 (3): 313-23.
73. Singh SK,Hawkins C,Clarke ID, et al.Identification of human brain tumour initiating cells.Nature. 2004;432 (7015): 396-401.
74. Zavadil J,Bottinger EP.TGF-beta and epithelial-to-mesenchymal transitions.Oncogene. 2005;24 (37): 5764-74.
75. Singh A,Settleman J.EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.Oncogene. 2010;29 (34): 4741-51.
76. Scheel C,Weinberg RA.Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links.Semin Cancer Biol. 2012;:23.
77. Pignatelli J,Tumbarello DA,Schmidt RP,Turner CE.Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial-mesenchymal transition.J Cell Biol. 2012;197 (3): 421-37.
78. Nakamura K,Yano H,Uchida H,Hashimoto S,Schaefer E,Sabe H.Tyrosine phosphorylation of paxillin alpha is involved in temporospatial regulation of paxillin-containing focal adhesion formation and F-actin organization in motile cells.J Biol Chem. 2000;275 (35): 27155-64.
79. Dabiri G,Tumbarello DA,Turner CE,Van de,Water L.Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta1 autocrine loop.J Invest Dermatol. 2008;128 (10): 2518-25.
80. Gligorijevic B,Wyckoff J,Yamaguchi H,Wang Y,Roussos ET,Condeelis J.N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors.J Cell Sci. 2012;125 (Pt 3): 724-34.
81. Kelly T,Mueller SC,Yeh Y,Chen WT.Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins.J Cell Physiol. 1994;158 (2): 299-308.
82. Tolde O,Rosel D,Vesely P,Folk P,Brabek J.The structure of invadopodia in a complex 3D environment.Eur J Cell Biol. 2010;89 (9): 674-80.
83. Kelly T,Yan Y,Osborne RL, et al.Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases.Clin Exp Metastasis. 1998;16 (6): 501-12.
84. Murphy DA,Courtneidge SA.The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function.Nat Rev Mol Cell Biol. 2011;12 (7): 413-26.
85. Linder S,Wiesner C,Himmel M.Degrading devices: invadosomes in proteolytic cell invasion.Annu Rev Cell Dev Biol. 2011;27:185-211.
86. Bowden ET,Barth M,Thomas D,Glazer RI,Mueller SC.An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation.Oncogene. 1999;18 (31): 4440-9.
87. Mueller SC,Yeh Y,Chen WT.Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells.J Cell Biol. 1992;119 (5): 1309-25.
88. Onodera Y,Hashimoto S,Hashimoto A, et al.Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities.EMBO J. 2005;24 (5): 963-73.
89. Badowski C,Pawlak G,Grichine A, et al.Paxillin phosphorylation controls invadopodia/podosomes spatiotemporal organization.Mol Biol Cell. 2008;19 (2): 633-45.
90. Gupta A,Lee BS,Khadeer MA, et al.Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast.J Bone Miner Res. 2003;18 (4): 669-85.
91. Sahu SN,Nunez S,Bai G,Gupta A.Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.Am J Physiol Cell Physiol. 2007;292 (6): C2288-96.
92. Buccione R,Caldieri G,Ayala I.Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix.Cancer Metastasis Rev. 2009;28 (1-2): 137-49.
93. Vega FM,Ridley AJ.Rho GTPases in cancer cell biology.FEBS Lett. 2008;582 (14): 2093-101.
94. Bellovin DI,Simpson KJ,Danilov T, et al.Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma.Oncogene. 2006;25 (52): 6959-67.
95. Dietrich KA,Schwarz R,Liska M, et al.Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity.Biol Chem. 2009;390 (10): 1063-77.
96. Kleer CG,Griffith KA,Sabel MS, et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Res Treat. 2005;93 (2): 101-10.
97. Kleer CG,Teknos TN,Islam M, et al.RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.Clin Cancer Res. 2006;12 (15): 4485-90.
98. Shikada Y,Yoshino I,Okamoto T,Fukuyama S,Kameyama T,Maehara Y.Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma.Clin Cancer Res. 2003;9 (14): 5282-6.
99. Wang W,Yang LY,Huang GW, et al.Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis.Br J Cancer. 2004;90 (12): 2349-55.
100. Clark EA,Golub TR,Lander ES,Hynes RO.Genomic analysis of metastasis reveals an essential role for RhoC.Nature. 2000;406 (6795): 532-5.
101. Hakem A,Sanchez-Sweatman O,You-Ten A, et al.RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis.Genes Dev. 2005;19 (17): 1974-9.
102. Simpson KJ,Dugan AS,Mercurio AM.Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.Cancer Res. 2004;64 (23): 8694-701.
103. Vega FM,Fruhwirth G,Ng T,Ridley AJ.RhoA and RhoC have distinct roles in migration and invasion by acting through different targets.J Cell Biol. 2011;193 (4): 655-65.
104. Bravo-Cordero JJ,Oser M,Chen X,Eddy R,Hodgson L,Condeelis J.A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia.Curr Biol. 2011;21 (8): 635-44.
105. LaLonde DP,Grubinger M,Lamarche-Vane N,Turner CE.CdGAP associates with actopaxin to regulate integrin-dependent changes in cell morphology and motility.Curr Biol. 2006;16 (14): 1375-85.
106. Kaulfuss S,von Hardenberg S,Schweyer S, et al.Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression.Oncogene. 2009;28 (45): 3971-82.
107. Carragher NO,Walker SM,Scott Carragher LA, et al.Calpain 2 and src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function.Oncogene. 2006;25 (42): 5726-40.
108. Friedl P,Noble PB,Zanker KS.T lymphocyte locomotion in a three-dimensional collagen matrix: expression and function of cell adhesion molecules.J Immunol. 1995;154 (10): 4973-85.
109. Friedl P,Wolf K.Plasticity of cell migration: a multiscale tuning model.J Cell Biol. 2010;188 (1): 11-9.
110. Gadea G,Sanz-Moreno V,Self A,Godi A,Marshall CJ.DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells.Curr Biol. 2008;18 (19): 1456-65.
111. Giampieri S,Manning C,Hooper S,Jones L,Hill CS,Sahai E.Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.Nat Cell Biol. 2009;11 (11): 1287-96.
112. Parri M,Taddei ML,Bianchini F,Calorini L,Chiarugi P.EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.Cancer Res. 2009;69 (5): 2072-81.
113. Sahai E,Marshall CJ.Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.Nat Cell Biol. 2003;5 (8): 711-9.
114. Sanz-Moreno V,Gadea G,Ahn J, et al.Rac activation and inactivation control plasticity of tumor cell movement.Cell. 2008;135 (3): 510-23.
115. Wolf K,Mazo I,Leung H, et al.Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis.J Cell Biol. 2003;160 (2): 267-77.
116. Wolf K,Wu YI,Liu Y, et al.Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion.Nat Cell Biol. 2007;9 (8): 893-904.
117. Wyckoff JB,Pinner SE,Gschmeissner S,Condeelis JS,Sahai E.ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo.Curr Biol. 2006;16 (15): 1515-23.
118. Friedl P,Wolf K.Proteolytic and non-proteolytic migration of tumour cells and leucocytes.Biochem Soc Symp. 2003;70 (70): 277-85.
119. Yoshida K,Soldati T.Dissection of amoeboid movement into two mechanically distinct modes.J Cell Sci. 2006;119 (Pt 18): 3833-44.
120. Coussens LM,Fingleton B,Matrisian LM.Matrix metalloproteinase inhibitors and cancer: trials and tribulations.Science. 2002;295 (5564): 2387-92.
121. Friedl P,Wolf K.Tumour-cell invasion and migration: diversity and escape mechanisms.Nat Rev Cancer. 2003;3 (5): 362-74.
122. Overall CM,Lopez-Otin C.Strategies for MMP inhibition in cancer: innovations for the post-trial era.Nat Rev Cancer. 2002;2 (9): 657-72.
123. Zucker S,Cao J,Chen WT.Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.Oncogene. 2000;19 (56): 6642-50.
124. Chambers AF,Groom AC,MacDonald IC.Dissemination and growth of cancer cells in metastatic sites.Nat Rev Cancer. 2002;2 (8): 563-72.
125. Fidler IJ.Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine.J Natl Cancer Inst. 1970;45 (4): 773-82.
126. Mori S,Chang JT,Andrechek ER, et al.Anchorage-independent cell growth signature identifies tumors with metastatic potential.Oncogene. 2009;28 (31): 2796-805.
127. Vande Pol SB,Brown MC,Turner CE.Association of bovine papillomavirus type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif.Oncogene. 1998;16 (1): 43-52.
128. Chen YC,Chen JH,Richard K,Chen PY,Christiani DC.Lung adenocarcinoma and human papillomavirus infection.Cancer. 2004;101 (6): 1428-36.
129. Fakhry C,Gillison ML.Clinical implications of human papillomavirus in head and neck cancers.J Clin Oncol. 2006;24 (17): 2606-11.
130. Ganguly N,Parihar SP.Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis.J Biosci. 2009;34 (1): 113-23.
131. Scheffner M,Werness BA,Huibregtse JM,Levine AJ,Howley PM.The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.Cell. 1990;63 (6): 1129-36.
132. Walboomers JM,Jacobs MV,Manos MM, et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J Pathol. 1999;189 (1): 12-9.
133. Sachdev S,Bu Y,Gelman IH.Paxillin-Y118 phosphorylation contributes to the control of src-induced anchorage-independent growth by FAK and adhesion.BMC Cancer. 2009;9:12.
134. Salgia R,Brunkhorst B,Pisick E, et al.Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.Oncogene. 1995;11 (6): 1149-55.
135. Subauste MC,Pertz O,Adamson ED,Turner CE,Junger S,Hahn KM.Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility.J Cell Biol. 2004;165 (3): 371-81.
136. Zouq NK,Keeble JA,Lindsay J, et al.FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas.J Cell Sci. 2009;122 (Pt 3): 357-67.
137. Frisch SM,Vuori K,Ruoslahti E,Chan-Hui PY.Control of adhesion-dependent cell survival by focal adhesion kinase.J Cell Biol. 1996;134 (3): 793-9.
138. Lin HM,Lee YJ,Li G,Pestell RG,Kim HR.Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage.Cell Death Differ. 2001;8 (1): 44-50.
139. Mori K,Hirao E,Toya Y, et al.Competitive nuclear export of cyclin D1 and hic-5 regulates anchorage dependence of cell growth and survival.Mol Biol Cell. 2009;20 (1): 218-32.
140. Jia Y,Ransom RF,Shibanuma M,Liu C,Welsh MJ,Smoyer WE.Identification and characterization of hic-5/ARA55 as an hsp27 binding protein.J Biol Chem. 2001;276 (43): 39911-8.
141. Fujita H,Kamiguchi K,Cho D,Shibanuma M,Morimoto C,Tachibana K.Interaction of hic- 5, a senescence-related protein, with focal adhesion kinase.J Biol Chem. 1998;273 (41): 26516-21.
142. Gao ZL,Deblis R,Glenn H,Schwartz LM.Differential roles of HIC-5 isoforms in the regulation of cell death and myotube formation during myogenesis.Exp Cell Res. 2007;313 (19): 4000-14.
143. Hornigold N,Craven RA,Keen JN,Johnson T,Banks RE,Mooney AF.Upregulation of hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis.Kidney Int. 2010;77 (4): 329-38.
144. Kim G,Davidson B,Henning R, et al.Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.Cancer. 2012;118 (6): 1543-53.
145. Madan R,Smolkin MB,Cocker R,Fayyad R,Oktay MH.Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.Hum Pathol. 2006;37 (1): 9-15.
146. Li HG,Xie DR,Shen XM,Li HH,Zeng H,Zeng YJ.Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma.World J Gastroenterol. 2005;11 (10): 1445-51.
147. Li BZ,Lei W,Zhang CY, et al.Increased expression of paxillin is found in human oesophageal squamous cell carcinoma: a tissue microarray study.J Int Med Res. 2008;36 (2): 273-8.
148. Wu DW,Cheng YW,Wang J,Chen CY,Lee H.Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting.Cancer Res. 2010;70 (24): 10392-401.
149. Wikstrom P,Marusic J,Stattin P,Bergh A.Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.Prostate. 2009;69 (8): 799-809.
150. Uhr JW,Pantel K.Controversies in clinical cancer dormancy.Proc Natl Acad Sci U S A. 2011;108 (30): 12396-400.